Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients
2021 · BMC Public Health · 18 citations
https://doi.org/10.1186/s12889-021-11427-y
P
Puck T. Pelzer
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
20
Papers
145
Citations
7
h-index
7
i10-index
Puck T. Pelzer is an academic researcher from International AIDS Vaccine Initiative. The author has contributed to research in topics: Tuberculosis Research and Epidemiology & Vaccine Coverage and Hesitancy & Immune responses and vaccinations. The author has an h-index of 7, co-authored 17 publications.
ORCID: 0000-0003-1648-0304Papers by this author
worksMeeting report: Virtual Global Forum on Tuberculosis Vaccines, 20–22 April 2021
2021 · Vaccine · 13 citations
https://doi.org/10.1016/j.vaccine.2021.08.094
Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysis
2022 · npj Vaccines · 11 citations
https://doi.org/10.1038/s41541-022-00554-1
Evidence required to evaluate the use of bacteriologically confirmed asymptomatic tuberculosis disease as a primary endpoint in prevention of tuberculosis disease vaccine licensure trials
2025 · The Lancet Respiratory Medicine · 2 citations
https://doi.org/10.1016/s2213-2600(25)00164-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat